Testosterone and coronary artery disease

Frontiers of Hormone Research

Volumn 37, Issue , 2009, Pages 91-107

  Nettleship, Joanne E ^a   Jones, Richard D ^a   Channer, K S ^b,c   Jones, T Hugh ^a,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^d BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANASTROZOLE; ANTIANGINA PECTORIS AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; FULVESTRANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LIPID; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; TESTOSTERONE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANDROGEN THERAPY; ANGINA PECTORIS; ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CASTRATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; EXPERIMENTAL ANIMAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MEDIATOR; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS; THROMBOSIS; ANIMAL; BLOOD; INTRAABDOMINAL FAT; MALE; METABOLISM;

ANGINA PECTORIS; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INSULIN RESISTANCE; INTERLEUKIN-1BETA; INTRA-ABDOMINAL FAT; MALE; RISK FACTORS; TESTOSTERONE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 59849129892     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000176047     Document Type: Review

References (86)

1. Rayner M, Mockford C, Boaz A: Coronary Heart Disease Statistics; in: British Heart Foundation Statistics Database. London, British Heart Foundation Education Department, 1998.
2. Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD: Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007; 39:366-371.
3. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM: Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002;87: 1550-1554.
4. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS: Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90:871-876.
5. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocri -nol Metab 2004;89:3313-3318.
6. McCrohon JA, Jessup W, Handelsman DJ, Cele -rmajer DS: Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999;99:2317-2322.
7. Zhang X, Wang LY, Jiang T Y, Zhang HP, Dou Y, Zhao JH, Zhao H, Qiao ZD, Qiao JT: Effects of testosterone and 17-beta-estradiol on TNF-alpha-induced E-selectin and VCAM-1 expression in endothelial cells: analysis of the underlying receptor pathways. Life Sci 2002;71:15-29.
8. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 2002;99:4055-4060.
9. Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K: Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 2002;530:129-132.
10. Glueck CJ, Glueck HI, Stroop D, Speirs, Hamer T, Tracy T: Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993;122:412-420.
11. Phillips GB, Pinkernell BH, Jing TY: The asso -ciation of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14: 701-706.
12. Pugh PJ, Channer KS, Parry H, Downes T, Jones TH: Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res 2002;28:161-173.
13. Beer NA, Jakubowicz DJ, Matt D W, Beer RM, Nestler JE: Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci 1996;311:205-210.
14. Caron P, Bennet A, Camare R, Louvet J P, Boneu B, Sie P: Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabol Clin Exp 1989;38:1010-1015.
15. Smith AM, English KM, Malkin CM, Jones RD, Jones TH, Channer K: Testosterone does not adve -rsely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 2005;152:285-291.
16. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, Jackson R, Beresford S, Howard B, Johnson K, Kotchen J, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
17. Barrett-Connor E, Khaw KT: Endogenous sex hormones and cardiovascular disease in men: a prospec -tive population-based study. Circulation 1988;78: 539-545.
18. Haffner SM, Mykkanen L, Valdez RA, Katz MS: Relationship of sex hormones to lipids and lipopro-teins in non-diabetic men. J Clin Endocrinol Metab 1993;77:1610-1615.
19. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E: Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82:682-685.
20. Dai WS, Gutai J P, Kuller LH, Laporte R, Falvo-Gerald L, Caggiula A: Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Cardiol 1984; 53:1259-1263.
21. Heller RF, Wheeler MJ, Micallef J, Miller N, Lewis B: Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin. Acta Endocrinol 1983;104:253-256.
22. Hromadova M, Hacik T, Malatinsky E, Riecansky I: Alterations of lipid metabolism in men with hypotestosteronemia. Horm Metab Res 1991;32: 392-394.
23. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM: Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003;166:95-102.
24. Barrett-Connor E: Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117:807-811.
25. Tenover JS: Effects of testosterone in the aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
26. Tripathy D, Shah P, Lakshmy R, Reddy KS: Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogo-nadism. Horm Metabol Res 1998;30:642-645.
27. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM: Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cyto-toxic chemotherapy. Clin Endocrinol 2001;55: 315-324.
28. Ly L P, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:4078-4088.
29. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN: Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165-1168.
30. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ: Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79:561-567.
31. Uyanik BS, Ari Z, Gumus B, Yigitoglu MR, Arslan T: Beneficial Effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J 1997;38:73-82.
32. Kapoor D, Goodwin E, Channer KS, Jones TH: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
33. Gliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W: Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121:35-43.
34. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD: Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111:261-269.
35. Barrett-Connor E, Khaw KT, Yen SS: Endogenous sex hormones in older men with diabetes mellitus. Am J Epidemiol 1990;132:895-901.
36. Zietz B, Cuk A, Hugl S, Buttner R, Straub RH, Bauer B, Daffner P, Scholmerich J, Palitzsch KD: Association of increased C-peptide serum levels and testosterone in type 2 diabetes. Eur J Intern Med 2000;11: 322-328.
37. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH: Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-917.
38. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L: Interrelation between plasma testosterone and plasma insulin in healthy adult men. Diabetologia 1992;35:173-177.
39. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB: Testosterone, sex hormone-binding globulin, and the development of diabetes in middle-aged men: prospective results from the Massachusetts male ageing study. Diabetes Care 2000;23:490-494.
40. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L: Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol 1996;143:889-897.
41. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, Lemort N, Thibult N, Joubert E, Balkau B, Eschwege E: Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care 2001;24:2149-2151.
42. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S: The effects of varying doses of testosterone on insulin sensitivity, plasma lipids, apolipoproteins and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87: 136-143.
43. Friedl KE, Jones RE, Hannan CJ Jr, Plymate SR: The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab 1989;68:971-975.
44. Marin P, Krotkiewski M, Bjorntrop P: Androgen tre -atment of middle-aged obese men: effects on metabo -lism muscle and adipose tissues. Eur J Med 1992;1: 329-336.
45. Vermeulen A, Goemaere S, Kaufman JM: Testos -terone, body composition and aging. J Endocrinol Invest 1999;22:110-116.
46. Haffner SM, Valdez RA, Stern M P, Katz MS: Obesity, body fat distribution and sex hormones in men. Int J Obes 1993;17:643-649.
47. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R: Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism 1990;39:897-901.
48. Phillips GB: Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabol 1993;42:116-120.
49. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM: Sex steroid hormones, upper body obesity and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-4527.
50. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D: Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res 1998;30:43-47.
51. Strain G W, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcopf RJ, Rosenfeld RS: Effect of massive weight loss on hypothalamic-pituitary- gonadal function in obese men. J Clin Endocrinol Metab 1988;66:1019-1023.
52. Rebuffe-Scrive M, Marin P, Bjorntrop P: Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991;15:791-795.
53. Marin P, Oden B, Bjorntrop P: Assimilation and mobilization of triglycerides in subcutaneous abdo -minal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80:239-243.
54. Boyanov MA, Boneva Z, Christov VG: Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
55. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K: Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atheroscler 1993;99:79-86.
56. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl F W, Haasis R, Hanke H: Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997;17:2192-2199.
57. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C: Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999;84:813-819.
58. Nathan L, Shi WB, Dinh H, Mukherjee TK, Wang X P, Lusis AJ, Chaudhuri G: Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001;98:3589-3593.
59. Nettleship JE, Jones TH, Channer KS, Jones RD: Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effects that is independent of the classical androgen receptor. Circ 2007;116:2427-2434.
60. Shores M, Matsumoto A, Slaon K, Kivlahan D: Low serum testosterone and mortality on male veterans. Arch Intern Med 2006;166:1660-1665.
61. Lauglin G, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
62. Keating N, O'Malley J, Smith M: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24: 4448-4456.
63. Jones RD, Nettleship JE, Kapoor D, Jones TH, Channer KS: Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005;5:141-154.
64. Hak A, Witteman J, DeJong F, Geerlings M, Hofman A, Pols H: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 2002;87:3632-3639.
65. van den Beld A, Bots M, Janssen J, Pols H, Lamberts S: Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003;157:25-31.
66. De Pergola G, Pannacciulli N, Ciccone M, Tartagni M, Rizzon P, Giogino R: Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obes 2003;27:803-807.
67. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, Ichio N, Wada K, Hasegawa G, Yoshikawa T: Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 2003;26:1869-1873.
68. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SWJ, van der Schouw YT: Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circ 2004;109:2074-2079.
69. Hamm L: Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol 1942;2:325-328.
70. Jaffe MD: Effect of testosterone cypionate on post-exercise ST segment depression. Br Heart J 1977;39: 1217-1222.
71. Wu SZ, Weng XZ: Therapeutic effects of an andro-genic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 1993;106:415-418.
72. English KM, Steeds R P, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-1911.
73. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della MP, Bonfigli B, Volpe M, Chierchia SL: Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666-1670.
74. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P: Effects of testosterone on coronary vaso-motor regulation in men with coronary heart disease. Circulation 1999;100:1690-1696.
75. Webb CM, Adamson DL, de Zeigler D, Collins P: Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83:437-439.
76. English KM, Jones RD, Jones TH, Morice AH, Channer KS: Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodil atory action of testosterone. Clin Sci 2000;99:77-82.
77. Jones RD, Pugh PJ, Jones TH, Channer KS: The vasodilatory action of testosterone: a potassium channel opening or a calcium antagonistic action? Br J Pharmacol 2003;138:733-744.
78. Jones RD, English KM, Jones TH, Channer KS: Test-osterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonistic action. Clin Sci 2004;107: 149-158.
79. Jones RD, Ruban LN, Morton IE, Roberts SA, English KM, Channer KS, Jones TH: Testosterone inhibits the prostaglandin F-2-alpha mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. J Endocrinol 2003;178:381-393.
80. 2+ channels. Biochem Biophys Res Commun 2004;318: 503-506.
81. Hall J, Jones RD, Jones TH, Channer KS, Peers C: Selective inhibition of L-type voltage-gated calcium channels in A7r5 cells by physiological levels of testosterone. Endocrinology 2006;147:2675-2680.
82. Jones RD, Jones TH, Channer KS: The influence of testosterone upon vascular reactivity. Eur J Endo crinol 2004;151:29-37.
83. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, Lee JH: Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 2002; 89:862-864.
84. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P: Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 2000;85:269-272.
85. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, De La Grange D, Lieberman EH, Ganz P Creager MA, Yeung AC, Selwyn AP: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26: 1235-1241.
86. Pugh PJ, Malkin CJ, Morris PD, Asif S, Jones RD, Jones TH, Channer KS: Prevalence of hypogona dism in men with coronary artery disease. J Am Coll Cardiol 2003;41:p344A.